Market Overview

Amarin Popped Amid Press Release In Friday's After-Hours Session

Related AMRN
Watch These 7 Huge Call Purchases In Thursday Trade
Benzinga's Option Alert Recap From July 12
Perkins Capital Management Inc Buys AmerisourceBergen Corp, Pentair PLC, Zagg Inc, Sells ... (GuruFocus)

Amarin Corporation plc (ADR) (NASDAQ: AMRN) shares are trading higher by $0.07 (3.7 percent) at $2.13 in Monday's session. The issue spiked in Friday's after-hours session, following the release of the American Heart Association's CHERRY abstract summaries.

In Friday's session, it finally cleared the horde of sellers that had been keeping a lid on the issue at the $2 area since mid-October. Friday's close of $2.04 (one penny off its high) marked the first time it closed above $2 since October 9, when it ended the session at $2.08.

The issue spiked nearly 22 percent to $2.45 (on 8,000 shares) just before the conclusion of the after-hours session at 8:00 p.m. ET.

On Monday morning, Amarin commented on the new data from a CHERRY study focusing on VascepA capsules, the highly-purified EPA drug therapy that may reduce residual risk in coronary heart disease patients already.

The reaction in Monday's session has been muted. After a flat open, it rallied to $2.19 before falling back to its current level. The rally is taking place on higher than average volume. So far, 1.5 million shares have traded compared to its 20-day average of 1.1 million, with less than four hours remaining in the session.

Editor's note: A previous version of this story did not mention that the abstracts were released on Friday afternoon.

Joel Elconin is the co-host of Benzinga's #PreMarket Prep, a daily trading idea radio show.

Do you like this article? Do you have suggestions for improvement? Please email

Posted-In: Premarket outlookTechnicals After-Hours Center Movers Trading Ideas


Related Articles (AMRN)

View Comments and Join the Discussion!